NCT05023759View on ClinicalTrials.gov

Anxiety Symptoms in Relation to Use of Hemp-derived, Full Spectrum Cannabidiol (CBD)

CompletedOBSERVATIONAL
Enrollment

30

Participants

Timeline

Start Date

June 1, 2020

Primary Completion Date

October 31, 2020

Study Completion Date

October 31, 2020

Conditions
Generalized Anxiety Disorder
Interventions
DIETARY_SUPPLEMENT

Formula30A Full Spectrum Hemp Cannabidiol 25mg Capsules

Formula30A Full Spectrum Hemp-Derived Cannabidiol (CBD) 25mg Capsules taken once daily for 8 weeks.

Trial Locations (6)

75126

Modern Medicine, Forney

76092

Destination Health, Southlake

Melville Medicine, Southlake

76201

NP Care Clinic, Denton

78539

Dr. Michael Jelinek, MD, Edinburg

00735

Dr. Jenaro Velez, MD, Ceiba

All Listed Sponsors
lead

Formula30A LLC

INDUSTRY

NCT05023759 - Anxiety Symptoms in Relation to Use of Hemp-derived, Full Spectrum Cannabidiol (CBD) | Biotech Hunter | Biotech Hunter